Citi initiated coverage of Regeneron (REGN) with a Neutral rating and $895 price target Multiple clinical data readouts should “keep ...

Also Read: Regeneron’s Dupixent COPD Sales To Reach $20B By 2026, Analyst Sees Larger Addressable Market The condition ...

Oral presentation shares head-to-head results for investigational combination pozelimab plus cemdisiran vs. ravulizumab in paroxysmal nocturnal ...

Regeneron should weather the Eylea biosimilar launch storm and continue to deliver long-term shareholder value. See why REGN ...

Regeneron released a strong financial report for Q3 and was the 15th of 16 in the last four years. Read why I upgrade REGN ...

Despite disappointing third-quarter results for Regeneron’s high-dose Eylea injection, analysts continued to be cautiously ...

U.S. drugmaker Regeneron Pharmaceuticals on Thursday reported weaker-than-expected quarterly sales of the higher dose version ...

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its target price decreased by Royal Bank of Canada from ...

The European Medicines Agency (EMA) approved Sanofi/Regeneron’s Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) ...

As with many other companies Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) makes use of debt. But should shareholders be worried about its use of debt? Generally speaking, debt only becomes a real ...

Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report third-quarter results on Oct. 31, 2024. The Zacks ...

Baron Funds, an investment management company, released its “Baron Health Care Fund” third quarter 2024 investor letter. A ...